Get the Weekly Intelligence Brief — top committee picks every Sunday.

GMED vs TNGX

Globus Medical vs Tango Therapeutics, Inc. — AI-powered side-by-side comparison
GMED
Globus Medical
71
Buy
VS
TNGX
Tango Therapeutics, Inc.
55
Buy
MetricGMEDTNGX
AI Score 71 55
Price $85.12 $26.32
P/E Ratio 21.45× -30.99×
ROE 11.8% -29.3%
Revenue Growth YoY
Gross Margin 68.5% 98.2%
Debt / Equity 0.02× 0.03×
Dividend Yield 0.0% 0.0%
RSI (14) 75.9 38.9
Beta 0.954 1.127
Expected Upside +0.1%

AI Committee View

Current Innellis committee reasoning for GMED versus TNGX.
GMED leads by 16 points.

GMED scores 71/100 (Buy) versus TNGX at 55/100 (Buy).

GMED Committee View
75% agreement
4 analysts

The primary driver is 5 consecutive earnings beats -- consistent execution. The main limiting factor is rsi at 76 is in overbought territory. The committee is constructive but not yet at full conviction.

Bull Case
  • 5 consecutive earnings beats -- consistent execution — Growth
  • Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
  • MACD histogram positive -- bullish momentum — Technical
Bear Case
  • RSI at 76 is in overbought territory — Technical
  • Price trading above the upper Bollinger Band -- stretched — Technical
TNGX Committee View
50% agreement
4 analysts

The committee is genuinely divided. Macro Analyst sees a compelling case — vix regime is low -- calm backdrop supports risk-taking. Risk Analyst remains cautious — bollinger bandwidth of 16.2% signals elevated volatility. This disagreement is itself the signal — the setup is not clean in either direction.

Bull Case
  • VIX regime is low -- calm backdrop supports risk-taking — Macro
  • Market regime is bullish (Bull market -- normal position sizing) — Macro
Bear Case
  • MACD histogram negative -- bearish momentum — Technical
  • Bollinger bandwidth of 16.2% signals elevated volatility — Risk
  • No news coverage in the last 14 days -- limited independent confirmation either way — News
Want the full breakdown?
Committee votes, technicals, and trade plans for both companies.
GMED Full Analysis TNGX Full Analysis